APLM
Apollomics Inc. Class A Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$30.06M
P/E Ratio
—
EPS
$-26.64
Beta
1.83
52W High
$40.02
52W Low
$3.66
50-Day MA
$19.01
200-Day MA
$14.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Fundamentals
| Revenue (TTM) | $6.93M |
| Gross Profit (TTM) | $6.93M |
| EBITDA | $-26.36M |
| Operating Margin | -124.80% |
| Return on Equity | -380.10% |
| Return on Assets | -72.30% |
| Revenue/Share (TTM) | $6.29 |
| Book Value | $-3.99 |
| Price-to-Book | 8.15 |
| Price-to-Sales (TTM) | 4.34 |
| EV/Revenue | 3.559 |
| EV/EBITDA | -0.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 380.80% |
| Shares Outstanding | $2.15M |
| Float | 594,350 |
| % Insiders | 0.00% |
| % Institutions | 0.40% |
Data last updated: 4/7/2026